This Stock Is Everything That’s Wrong with the Markets

[BREAKING] As we published this Thursday morning, news broke that Valeant is now under federal investigation in Massachusetts and New York for its drug-pricing practices. VRX shares were down -11.5% at open. Stay tuned here.

Every once in a while, a single company combines virtually all of the market’s most toxic forces. Today I feel it’s my job to expose such a company for the bad investment it is. Here’s why.

  1. It’s got a risky and predatory business model.
  1. It’s leveraged up to the hilt, with $30 billion of debt on just $9 billion in revenue in the trailing 12 months.
  1. It’s on the radar of politicians, which is trouble for shareholders.

And here’s the real problem…

  1. It’s widely owned by investors like you. Even if you don’t realize it, you may own this stock in any of the seven ETFs that hold it as a component.

Already the stock dropped -25% in September. In a Super Crash, it’s going to be much worse. This stock is a yo-yo. It gained +6.48% yesterday, but the day before it lost -4.21%.

And it’s really in trouble now.

The company I’m talking about is Valeant Pharmaceuticals International Inc. (NYSE:VRX). Today let’s just focus on Valeant’s cynical and leveraged business model.

This is a $60 billion multinational pharmaceutical company with a portfolio of prescription drugs, including Kinerase and Wellbutrin, one of the most frequently prescribed antidepressants in the U.S., and consumer products, mostly in the skin, eye, and oral care segments. Valeant’s revenues more than doubled from 2012 to 2014, jumping from $3.48 billion to $8.25 billion in just two years.

But look closely as how it did that…

VRX has achieved its status as one of the fastest-growing pharmaceutical companies in the world while taking advantage of every conceivable legal and tax loophole available. It has enriched its management and a small group of hedge funds while contributing to skyrocketing healthcare costs and leaving the bill for U.S. taxpayers and consumers to pay.

Valeant is the poster child for putting profits before principle.

VRX buys other companies using enormous amounts of junk bonds, then fires most of their employees to cut costs, and then raises the prices of the drugs it acquires. It spends only 3% of sales on research and development of new drugs compared to 15-20% for other drug companies. And the company pays very low taxes because it is officially based in Canada though it operates from New Jersey. Take a look at the image below (from Wikipedia) for a sense of what Valeant’s “growth” has really looked like.



growth extreme
Click to Enlarge

The company claims that it isn’t “good” at R&D, but that is just an excuse because it has decided that it is more lucrative to buy other companies’ drugs and then mark up their prices. According to an analysis performed by Deutsche Bank Securities, VRX’s average annual drug price increase has risen from 21% in 2012 to 66% in 2015. The 66% increase is five times higher than its nearest rivals. For example, Pfizer has raised prices by an average of only 9.6% this year according to Deutsche Bank. One example is the diabetes drug Glumetza, which belong to Salix Pharmaceuticals. Valeant acquired Salix this year and promptly raised the price of Glumetza from around $896 to $10,000. (Look for the October 5 New York Times report on this.)

So while the Federal Reserve is busy telling people that inflation is too low, drug prices are experiencing hyperinflation. The Fed can get away with promulgating this nonsense because most consumers don’t pay for their own drugs – insurance companies and the government pick up the tab. But that does little to bend the healthcare cost curve.

The potential problem for VRX is that it has $30 billion of debt that it has to service. The company is dependent on its ability to keep making debt-funded acquisitions and raising drug prices. In the current market and political environment, its ability to do both are coming into question.

In other words, VRX is a highly leveraged “serial acquirer” that buys other companies only to fire their workers and hike the prices of their drugs for consumers whose costs fall mostly on insurance companies and the U.S. government. This is the state of corporate finance and healthcare policy in America in the Age of Obama.

But it’s about to backfire…

Next time I’ll show you something even more insidious.

9 Responses to “This Stock Is Everything That’s Wrong with the Markets”

  1. There must be a balance between revenue drive vs a sense of humanity. VRX is an organization fueled by greed with no second thought of those needing the medication. It is not surprising, just look at the company key shareholders. The whole idea is to balloon up the market cap of the company, in short term look great for all these hedge fund, then cash out before the balloon burst. I really hope the stock get massive sell down. However I am very concern about the effect of VRX effect. Developing new medicine is a very expanisve exercise, mostly support by their earning by existing products. It will be extremely damaging if the authority implement a ridiculous policy that will kill the industry.
    Looking at the situation profiteering is the key driver of the financial market, even at the expanse of our fellowmen, even our soul. We all love Nike, great product with great margin! It doesn’t matter to us, thousands of jobs are allocated outside of US, as long as we can milk every ounce of profit and revenue appreciation quarter after quarter. As a consumer I had stop buying Nike (anyone see how their vendors produced the footwear, stupid to greatly over paid for those footwear.), but as a shareholder, I love the stock, I had it for last 3 years and most like existing in Dec 2015. In term of profiteering, disregard the debt different between Nike and Valent, what did Valent did wrong? Key part of Under Armor and Nike market is within U.S., the company don’t care those thousands of people, that help them great, it’s good business. We applaud them, we love their shares!

  2. My words cannot express how overwhelmed I was when I saw your words coming true in the market. Little did I know about the story and I was thinking to buy as it fell to 60 dollars. When I received the email I thought how can one short in this already down market and with this share at such low price relative to its past price. Honestly I did not believe the story. Today I am spellbound. Trust me I admire you

Leave a Comment

View this page online: